Effect of flutamide on survival in patients with pancreatic cancer: results of a prospective, randomised, double blind, placebo controlled trial
Objectives: To assess whether flutamide (Drogenil), a pure androgen receptor blocking agent, improves survival in patients with pancreatic carcinoma and thus whether testosterone is a major growth factor for this tumour. Design: A prospective, randomised, double blind placebo controlled trial. Subje...
Guardat en:
| Publicat a: | BMJ |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
1998
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC28589/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9641928/ https://ncbi.nlm.nih.govhttps://doi.org/10.1136/bmj.316.7149.1935 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|